Nintedanib in Patients With Advanced Esophagogastric Cancer

Summary

This is a phase II study of Nintedanib in patients with metastatic or recurrent esophagogastric cancer. The goal of the study is to evaluate the efficacy of Nintedanib, an orally available triple kinase inhibitor targeting the receptors of the vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and fibroblast growth factor (FGF) receptor pathways.

Timeline

Start

2014-09-04

Primary completion

2020-04-22

Completion

2020-04-22

Drugs

Indications